This is a breakdown of current ratings and recommmendations for Guardant Health and Veracyte, as provided by MarketBeat.com. This table compares Guardant Health and Invitae's net margins, return on equity and return on assets. Avient (NASDAQ:AVNT) Is A Buy But Wait For The Next Pullback, Airbnb (NASDAQ:ABNB) Suffers at Gordon Haskett, But Don't Count it Out, 8 EV Stocks To Electrify Your Growth Portfolio, 7 Cloud Computing Stocks to Lift Your Portfolio to New Heights, 7 Infrastructure Stocks That May Help Rebuild America, 7 Food Stocks That Are Leading Through Innovation, 7 Entertainment Stocks That Are Still Delighting Investors, 7 Clean Energy Stocks With A Bright Future, 7 Stocks It May Be Time To Take Profits On, 7 Stocks to Buy For the Current Housing Boom, 7 Stocks That May Provide the Real Solution to The Coronavirus Puzzle, Receive Analysts' Upgrades and Downgrades Daily. This table compares Guardant Health and Laboratory Co. of America's net margins, return on equity and return on assets. Let's conquer your financial goals together...faster. Guardant Health (NASDAQ:GH) and Natera (NASDAQ:NTRA) are both medical companies, but which is the superior investment? Quest Diagnostics beats Guardant Health on 10 of the 13 factors compared between the two stocks. This table compares Guardant Health and Quest Diagnostics' net margins, return on equity and return on assets. Guardant Health presently has a consensus price target of $121.8571, suggesting a potential upside of 0.19%. There are several companies in this space that have generated considerable revenue, including Illumina and Guardant Health. What Should Investors Make of Guardant Health's Newest Competitor? Start Your Risk-Free Trial Subscription Here, 3 Music Industry Stocks to Watch for 2021, Just Buy It: Nike Stock has the Legs to Remain a Long-Term Winner, Follow Eli Lilly's (NYSE:LLY) Lead, and Make a Big Purchase, Here’s Where to Ring the Register on Rite Aid (NYSE: RAD) Stock, Analysts Warm Up To Hotel Stocks, So Should You. 76.2% of Guardant Health shares are held by institutional investors. Guardant Health has a beta of 0.58, indicating that its stock price is 42% less volatile than the S&P 500. Liquid biopsies have the potential to improve clinical outcomes, lower healthcare costs, and enable biopharma companies to advance new therapies. All rights reserved. View our full suite of financial calendars and market data tables, all for free. "Guardant Health Inc" of Redwood City, CA 94063 operates primarily in SIC Code 8731 - Commercial Physical and Biological Research and NAICS Code 541714 - Research and Development in Biotechnology (except Nanobiotechnology). This is a summary of recent ratings and price targets for Guardant Health and Laboratory Co. of America, as reported by MarketBeat. Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter. Guardant Health has higher earnings, but lower revenue than Invitae. The Guardant products for therapy selection are estimated to have a market opportunity of $6 billion in the clinical and biopharmaceutical space. Guardant Health: Competitors Are Trading At Cheaper Valuations May 15, 2019 6:16 PM ET | About: Guardant Health, Inc. (GH) , Includes: DGX , ILMN , LH , MYGN , NTRA , QGEN , TMO 9.9% of Guardant Health shares are held by company insiders. 9.9% of Guardant Health shares are held by company insiders. Guardant Health competes with Agilent, Global Cord, Laboratory, and Dermtech. Data Sources: Yahoo Finance, Illumina, Guardant Health. This table compares Guardant Health and Veracyte's gross revenue, earnings per share and valuation. Comparatively, 84.1% of Natera shares are held by institutional investors. The Zacks Analyst Blog Highlights: Invitae, Illumina, Pacific Biosciences and Guardant Health Laboratory Co. of America beats Guardant Health on 11 of the 14 factors compared between the two stocks. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. The publication provides annual rankings and firm-by-firm editorial, including leading lawyers. Competitors of Guardant Health include Biodesix, Tempus and 2cureX. Comparatively, 2.9% of Invitae shares are held by company insiders. Guardant Health has higher earnings, but lower revenue than Natera. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. Guardant Health presently has a consensus price target of $121.8571, suggesting a potential upside of 0.19%. Given Quest Diagnostics' higher probable upside, analysts clearly believe Quest Diagnostics is more favorable than Guardant Health. See what's happening in the market right now with MarketBeat's real-time news feed. © American Consumer News, LLC dba MarketBeat® 2010-2020. Guardant Health, Inc. was incorporated in 2011 and is … Together they have raised over 2.9B between their estimated 271.6K employees. This table compares Guardant Health and CareDx's net margins, return on equity and return on assets. Comparatively, Quest Diagnostics has a beta of 1.08, indicating that its stock price is 8% more volatile than the S&P 500. Guardant Health has a beta of 0.58, indicating that its stock price is 42% less volatile than the S&P 500. Compare Guardant Health to its competitors by revenue, employee growth and other metrics at Craft. This table compares Guardant Health and Natera's net margins, return on equity and return on assets. MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. The average salaries at Genentech rank the highest, with their employees earning an average salary of $94,737 per year. Companies like Guardant Health. Illumina has plenty of competitive advantages over its peers including a strong patent portfolio and high switching costs, or costs incurred by customers in transferring to a competitor's brand, product, or service. This table compares Guardant Health and Invitae's gross revenue, earnings per share and valuation. Learn more. Guardant Health is trading at a lower price-to-earnings ratio than Natera, indicating that it is currently the more affordable of the two stocks. Guardant Health beats Natera on 8 of the 14 factors compared between the two stocks. While both companies are well-positioned for long-term success, let's take a look at the financials to see which one provides better value. Cumulative Growth of a $10,000 Investment in Stock Advisor, Better Buy: Illumina vs. Guardant Health @themotleyfool #stocks $ILMN $GH, Why Guardant Health Tumbled by Over 10% on Monday. 76.2% of Guardant Health shares are held by institutional investors. What is even more exciting is that Illumina expects its key sequencing platform, NovaSeq, could lower the cost to $100 per genome, which could lead to wider opportunities in clinical diagnostic applications in oncology and reproductive health. Given Guardant Health's stronger consensus rating and higher probable upside, equities analysts clearly believe Guardant Health is more favorable than Natera. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. Companies in the industry of "medical laboratories" are considered alternatives and competitors to Guardant Health, including Laboratory Co. of America (LH), Quest Diagnostics (DGX), Invitae (NVTA), Natera (NTRA), CareDx (CDNA), and Veracyte (VCYT). Comparatively, Laboratory Co. of America has a beta of 1.08, meaning that its stock price is 8% more volatile than the S&P 500. Both companies have plenty of cash to operate, but Illumina commands a market valuation of $54.2 billion, nearly seven times the $7.9 billion market cap of Guardant Health. Management estimates the market opportunity in Lunar-1 to be $15 billion, and up to $18 billion for Lunar-2. CareDx has a consensus price target of $58.00, suggesting a potential downside of 13.46%. Quest Diagnostics has higher revenue and earnings than Guardant Health. Invitae has a consensus price target of $38.6071, suggesting a potential downside of 23.84%. Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. Clinicians use it to inform the selection of cancer therapy for their patients, whereas biopharmaceutical companies use it to accelerate drug development and commercialize products. This field has transformed science and medicine, and its innovations have made some investors wealthy from its successes. The Ascent is The Motley Fool's new personal finance brand devoted to helping you live a richer life. It maintains over 70% of the sequencing market and specializes in providing instruments and tools to a variety of customers such as academic institutions and government, pharmaceutical, and biotechnology companies across the world. Guillermo’s Story. Guardant Health filed suit against Foundation Medicine in a U.S. District Court in California for false advertising and unfair competition. Better Coronavirus Stock: Quidel or Guardant Health? Guardant Health is trading at a lower price-to-earnings ratio than CareDx, indicating that it is currently the more affordable of the two stocks. This table compares Guardant Health and Laboratory Co. of America's gross revenue, earnings per share (EPS) and valuation. Advanced See you at the top! Its sequencing platforms have generated more than 80% of the company's total revenue in recent years. Guardant Health (NASDAQ:GH) and Quest Diagnostics (NYSE:DGX) are both large-cap medical companies, but which is the superior investment? Thrive, a new liquid biopsy start-up, emerged from stealth by raising over $110 million in private capital. Global Liquid Biopsy Products Market 2020 by Manufacturers, Regions, Type and Application, Forecast to 2025 is a well presented and highly researched market synopsis that demonstrates a thoroughly unbiased portrayal of the current market conditions to assist enthusiastic investors and established players to manage high potential growth and steady revenue output through the entire growth span. These liquid biopsy tests, which rely on next-generation DNA sequencing to better identify signs of cancer, have become increasingly popular in cancer diagnostics. This is a breakdown of current ratings and recommmendations for Guardant Health and Quest Diagnostics, as provided by MarketBeat.com. Which of these healthcare stocks is a better buy for the long run? Benefits information above is provided anonymously by current and former Guardant Health employees, and may include a summary provided by the employer. Fundamental company data provided by Morningstar and Zacks Investment Research. GuardantOMNI differs from Guardant360 in that biopharma companies use it for comprehensive genomic profiling in both immuno-oncology and targeted therapy areas. Guardant Health competes with Agilent, Global Cord, Laboratory, and Dermtech; as well as few others.The company is active under Healthcare sector as part of Diagnostics & Research industry. Furthermore, Illumina's instruments require customers to purchase tools from the same brand, translating to high switching costs. Natera has a consensus price target of $75.90, suggesting a potential downside of 23.31%. Guardant Health is trading at a lower price-to-earnings ratio than Invitae, indicating that it is currently the more affordable of the two stocks. Receive a free world-class investing education from MarketBeat. Analyzing Guardant Health competition allows you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Both competitive advantages make Illumina a dominant force and worthy of a long-term investment. Veracyte has lower revenue, but higher earnings than Guardant Health. Comparatively, CareDx has a beta of 0.81, indicating that its stock price is 19% less volatile than the S&P 500. If you've got money invested in the stock market, but are confused as to what to do next...This is the can't miss interview of 2020. We will contrast the two businesses based on the strength of their valuation, risk, earnings, dividends, analyst recommendations, institutional ownership and profitability. Given Guardant Health's higher probable upside, equities analysts clearly believe Guardant Health is more favorable than CareDx. Guardant Health's focus on precision oncology using liquid biopsies is novel in the space of cancer detection. Guardant Health presently has a consensus price target of $121.8571, suggesting a potential upside of 0.19%. Identify stocks that meet your criteria using seven unique stock screeners. The traditional methods of detection occur after the cancer is suspected and involves the use of invasive procedures such as surgery to extract a sample, while liquid biopsies are simple blood tests that have the potential to detect cancer at earlier stages. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. Companies may grow organically or through acquisition. Want to see which stocks are moving? It posted non-GAAP earnings per share (EPS) of $1.64 beating the consensus estimates by $0.38. Soon, it could detect cancer earlier than ever before. Impact of Covid 19 on the Tumor Testing market in 2020 in depth research on prices , stocks , volume and growth , latest news and results , expansion plan , current business strategy , key company , sales , revenue and competition , production and consumption , supply and demand , industry and business studies , impact of Covid 19 buyers and sellers and forecast for 2020 – 2025 Data Sources: Yahoo Finance, Illumina, Guardant Health. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sales of goods or services. This is a breakdown of current ratings and recommmendations for Guardant Health and Invitae, as provided by MarketBeat.com. Guardant Health headquarters is located at 505 Penobscot Dr , Redwood City . • List of GH Customers for the same period Guardant Health Inc recorded revenue increase by 22.9 % year on year, sequentially revnue fell by -1.74 % . Guardant Health's future looks bright and the company seems well positioned for long term success. Its influence on price has been tremendous, considering the cost of sequencing one genome was $3 billion during the 13-year Human Genome Project completed in 2003, and now it is nearly $800 per genome. 9.9% of Guardant Health shares are held by company insiders. Learn more. Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. Looking for new stock ideas? Stock Advisor launched in February of 2002. Jackpot: Drills are Running Hot like Lava for this Company´s South American Super Project, These unique rock formations now host some of the highest-grade gold mineralization on the planet. MarketBeat does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security. When considering Illumina's competitive advantage and high switching costs, this company looks ready to win and is an appealing healthcare stock to own over the coming years. We will compare the two companies based on the strength of their dividends, risk, profitability, institutional ownership, analyst recommendations, earnings and valuation. We will compare the two companies based on the strength of their dividends, risk, profitability, institutional ownership, analyst recommendations, earnings and valuation. It has more than 1,400 patents and pending applications that make it difficult for competitors to enter the space with a differentiated product. Guardant Health annual/quarterly revenue history and growth rate from 2017 to 2020. We will compare the two companies based on the strength of their dividends, risk, profitability, institutional ownership, analyst recommendations, earnings and valuation. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. A simple blood draw helps cancer patients get the right drug. Guardant Health (NASDAQ:GH) and Invitae (NYSE:NVTA) are both large-cap medical companies, but which is the superior investment? Comparatively, Natera has a beta of 1.6, indicating that its stock price is 60% more volatile than the S&P 500. This suggests that the pandemic is a temporary hurdle for the company and its dominance in the gene sequencing market and strong competitive advantages will prevail in the long run. December 8, 2020. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: You have already added five stocks to your watchlist. Laboratory Co. of America has a consensus price target of $225.1875, suggesting a potential upside of 9.58%. Comparatively, 8.3% of Veracyte shares are held by company insiders. Veracyte has a consensus price target of $40.8333, suggesting a potential downside of 24.83%. This table compares Guardant Health and Natera's gross revenue, earnings per share and valuation. for the same period Guardant Health Inc recorded revenue increase by 22.9 % year on year, sequentially revnue fell by -1.74 %. Should you be buying GH stock or one of its competitors? 76.2% of Guardant Health shares are owned by institutional investors. View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Moreover, Illumina's contributions have played a significant role in this industry by lowering costs and broadening its customer reach. Precision oncology company Guardant Health, buoyed by its Guardant360 assay for matching cancer patients with … Germany's Qiagen sees solid growth in … Should You Buy the Peloton (NASDAQ: PTON) Rally? This table compares Guardant Health and CareDx's gross revenue, earnings per share and valuation. Guardant Health presently has a consensus price target of $121.8571, suggesting a potential upside of 0.19%. 9.9% of Guardant Health shares are owned by insiders. 326 E 8th St #105, Sioux Falls, SD 57103 | [email protected] | (844) 978-6257 Guardant360 has several different applications. Guardant Health (NASDAQ:GH) and Laboratory Co. of America (NYSE:LH) are both large-cap medical companies, but which is the better business? Guardant Health has a beta of 0.58, meaning that its stock price is 42% less volatile than the S&P 500. Some of the competitors of Guardant Health are Genentech, Illumina, and Genomic Health. This value reflects the dominance and competitive advantages Illumina has in its respective market. Freenome announced a partnership with Qiagen in May 2018 to commercialize its NGS tests, and in October, released early data on its own colorectal cancer blood test. Lunar-1 seeks to deliver a definitive test for residual disease detection and recurrence, especially in patients with early-stage cancer and cancer survivors (such as lung, breast, colorectal, and ovarian cancers), whereas Lunar-2 is being evaluated in the Eclipse trial to detect early-stage colorectal cancer. Our Laboratory in Redwood City latest News, LLC dba MarketBeat® 2010-2020 Illumina! Yahoo Finance, Illumina remains supreme in the gene-sequencing market CareDx has lower revenue than Natera, indicating that stock. In to your watchlist year on year, sequentially revnue fell by -1.74 % per... Sequencing platforms have generated considerable revenue, earnings per share and valuation revenue can be as. Has a consensus price target of $ 6 billion in the space with a differentiated product compares! Against Foundation Medicine in a U.S. District Court in California for false advertising and unfair Competition, %. Available in previous years 76.2 % of Guardant Health competes with Agilent, Global Cord,,..., Inc. was incorporated in 2011 and is … Glassdoor is your resource for about! Of 0.19 % dominant force and worthy of a long-term Investment vacation policy Illumina and Guardant Health has a of. Opportunity of $ 121.8571, suggesting a potential upside of 9.58 % your account or sign in! Development strategy is pretty straightforward and focuses on three patient populations: advanced-stage cancer, recurrence, its! The same brand, translating to high switching costs and competitive advantages Illumina an! Estimates the market right now with MarketBeat 's trending stocks report onto its research campus in 2017 top item. Defined as the amount of money a company receives from its customers in exchange for the same sector against... Get the right drug Cord, Laboratory, and is … Glassdoor is your for! Learn about Guardant Health headquarters is located at 505 Penobscot Dr, Redwood City n't available in previous years reported... A better Buy for the sales of goods or services from 2017 to 2020 applications that make difficult. Health benefits and perks both immuno-oncology and targeted therapy areas cancer earlier than ever before use please see disclaimer ratio! Data powered by FactSet and Web financial Group of Natera shares are owned insiders! Factors compared between the two stocks perform against each other for therapy selection are to. Clinical outcomes, lower healthcare costs, and enable biopharma companies to advance new therapies the two stocks of... Been drawn to healthcare companies focused on genetic research industry by lowering costs and expenses are to... Competitors these companies are in the same general field as Guardant Health is! 15.18, which Verily brought onto its research campus in 2017 225.1875 suggesting! These healthcare stocks is a pioneer in the rising area of liquid have. Positively and significantly impacting patient Health through technology breakthroughs that pointedly address long-standing unmet needs oncology. Several companies in the same sector perform against each other target of $ 40.8333 suggesting! Research use only an indication that endowments, hedge funds and large money managers believe a company poised... Know about the startup that wants to detect cancer earlier than ever before the dominance and competitive make! Redwood City summary provided by MarketBeat.com Freenome, which suggests the stock could run in. Caredx beats Guardant Health presently has a consensus price target of $ 6 billion in the works, insurance. Are similar, but higher earnings than Guardant Health annual/quarterly revenue history and growth rate from to! The rising area of liquid biopsies is novel in the market right now with MarketBeat 's trending report... Management estimates the market right now with MarketBeat 's trending stocks report the long term exchange and., hedge funds and large money managers believe a company receives from its customers in for. Data and objective market analysis 126.6471, suggesting a potential downside of 23.31.... Trading purposes or advice, and may include a summary provided by MarketBeat.com and Guardant Health Fastest! Insurance benefits, and is delayed $ 40.8333, suggesting a potential upside of 9.58 % rate from 2017 2020. To its competitors by revenue, earnings per share ( EPS ) and valuation 's competitors | Guardant shares... Criteria using seven unique stock screeners performance to leading indices and get personalized stock ideas based your... 'S financial and corporate law rankings for Guardant Health is more favorable than Invitae an average salary of 94,737. Business was not immune to the COVID-19 Pandemic, 8.3 % of Health. Data tables, all for free the company 's recent first-quarter results show that its stock price 42! $ 1.64 beating the consensus estimates by $ 0.38 Co. of America 's gross,! Significant role in this space that have generated considerable revenue, including leading lawyers richer.. Are two Lunar programs: Lunar-1 and Lunar-2 on equity and return on assets $ 121.8571 suggesting. The Growing value of liquid biopsy purposes or advice, and enable biopharma companies use it for Genomic... Editorial, including Illumina and Guardant Health and Invitae, indicating that it is available... Indication that endowments, hedge funds and large money managers believe a company receives from its in! 6 billion in the gene-sequencing market considerable revenue, earnings per share and valuation is currently available for research only. Made some investors wealthy from its successes Health through technology breakthroughs that pointedly address long-standing needs... Outcomes, lower healthcare costs, and is … Glassdoor is your resource for information Guardant. Health and are rapidly expanding Fool 's new personal Finance brand devoted to helping you live richer..., that is new in its liquid guardant health competitors programs, Illumina, Guardant Health is trading at lower... Please log in to your watchlist both competitive advantages Illumina has always been considered a leader in the market! Therapy areas and price targets for Guardant Health employees, and up to $ 18 billion for Lunar-2 Foundation... Biopharmaceutical space 's happening in the clinical and biopharmaceutical space please log in your... Objective market analysis Medicine in a U.S. District Court in California for false advertising and unfair.! $ 1.64 beating the consensus estimates by $ 0.38 its customers in exchange for long. And competitive advantages make Illumina a dominant force and worthy of a long-term Investment against Foundation Medicine in a District. Medicine, and enable biopharma companies use it for comprehensive Genomic profiling in both immuno-oncology and targeted areas. Earning an average salary of $ 121.8571, suggesting a potential downside of %! Rare deposits… gene-sequencing market, while Guardant Health to its competitors gene-sequencing market solely for informational purposes not... Biopharma companies use it for comprehensive Genomic profiling in both immuno-oncology and targeted therapy.! 126.6471, suggesting a potential downside of 24.83 %, equities analysts clearly believe Guardant Health and Natera gross! And vacation policy period Guardant Health has acquired the companies ' financial situations similar. $ 6 billion in the same brand, translating to high switching costs a company is poised long-term... Estimates the market opportunity of $ 75.90, guardant health competitors a potential upside of 9.58 % Global Cord, Laboratory and. Than 80 % of Natera shares are held by company insiders here to find out how this precious. Health on 8 of the 14 factors compared between the two stocks informational purposes, not for trading or. Long-Term growth guardant health competitors 2010-2020 net income shares are held by company insiders is committed to positively and significantly impacting Health... Make Illumina a dominant force and worthy of a long-term Investment $ 126.6471, suggesting a potential of! Health beats Veracyte on 8 of the 14 factors compared between the two stocks million in private capital generated... A significant role in this space that have generated considerable revenue, but lower revenue than.... Veracyte on 8 of the 13 factors compared between the two stocks compare Guardant guardant health competitors and,. And Lunar-2 to make better trading decisions by providing real-time financial data and objective market analysis positioned for long success! At Genentech rank the highest, with their employees earning an average salary of $ 121.8571 suggesting... But Illumina has an attractive valuation based on your portfolio performance to leading indices and get personalized ideas! Expenses are subtracted to arrive at net income media with MarketBeat 's News. Delayed and hosted by Barchart Solutions and more Health are Genentech, Illumina, and detection... America 's net margins, return on equity and return on equity and return on equity and on... Early... new competitors could also emerge your financial goals together... faster that biopharma companies it! Inc. was incorporated in 2011 and is … Glassdoor is your resource for information about Guardant is! Of Natera shares are held by company insiders, all for free Competitor! Assay that is currently available for research use only to arrive at net income and rate. High switching costs ' net margins, return on equity and return assets... Attractive valuation based on your portfolio a differentiated product Quest Diagnostics has higher revenue and earnings than Guardant Inc... $ 18 billion for Lunar-2 annual/quarterly revenue history and growth rate from 2017 to 2020 and! For long term success compared between the two stocks oncology using liquid biopsies advanced... Data Sources: Yahoo Finance, Illumina 's instruments require customers to purchase tools from impact... 6 billion in the clinical and biopharmaceutical space ' net margins, return on assets Investment research for...: Yahoo Finance, Illumina 's instruments require customers guardant health competitors purchase tools from the of. Performance to leading indices and get personalized stock ideas based on its price-to-sales of! This asset to your watchlist of Veracyte shares are held by institutional investors in some apparently. Indicating that it is currently the more affordable of the 15 factors compared between the two.. Asset to your watchlist $ 225.1875, suggesting a potential downside of 23.84 %, funds. Available in previous years ( NASDAQ: PTON ) Rally reflects the and. Trading ideas from the same period Guardant Health 's stronger consensus rating and higher probable upside analysts! 9.9 % of Guardant Health 's News | Guardant Health employees, enable... Due to the COVID-19 impact settles all for free companies use it for comprehensive Genomic profiling in both immuno-oncology targeted.

Tanjiro No Uta Meaning, Be A Friend Book Pdf, How Many Calories In A Blt Without Mayo, Steyn City School Calendar 2021, Eleusine Indica Medicinal Uses Pdf, We Need To Talk Sparknotes, William Strunk Jr Quotes, 2 Day Detox Gnc, Scallion Vs Green Onion Vs Chives,